Literature DB >> 1387333

Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance.

Y Sharabi1, V S Abraham, M Sykes, D H Sachs.   

Abstract

We have recently described a non-myeloablative conditioning regimen permitting engraftment of allogeneic bone marrow in mice which involves administration of anti-CD4 (GK1.5) plus anti-CD8 (2.43) monoclonal antibodies in vivo, 3 Gy whole body irradiation, plus 7 Gy thymic irradiation. B10 (H-2b) mice prepared by this regimen and infused with unmanipulated B10.D2 (H-2d) bone marrow develop permanent mixed lymphohematopoietic chimerism and specific tolerance to donor skin grafts. We now demonstrate that mixed chimerism persists longer than 170 days in the lymphoid tissues including spleen, thymus and bone marrow of such animals, and that equivalent levels of donor chimerism are observed in both T and B cell compartments. In addition stable mixed chimeras were found to be unresponsive to host (B10) and donor (B10.D2) stimulator cells in mixed lymphocyte reaction and in cell mediated lympholysis assays, while responses to a third party (B10.BR, H-2k) were intact. Persistent chimerism was found to be necessary for the maintenance of skin graft tolerance in these animals, since in vivo depletion of donor cells by treatment with an anti-H-2d (34-2-12) monoclonal antibody resulted in the subsequent rejection of donor skin grafts. These studies demonstrate that mixed allogeneic chimeras produced using this regimen are specifically tolerant to donor in vitro and in vivo, and that persistence of donor chimerism is critical for the maintenance of tolerance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387333

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  17 in total

Review 1.  Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution.

Authors:  K L Gandy
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 2.  Mixed chimerism and split tolerance: mechanisms and clinical correlations.

Authors:  David P Al-Adra; Colin C Anderson
Journal:  Chimerism       Date:  2011 Oct-Dec

3.  2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25- T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice.

Authors:  Yanyan Qu; Baojun Zhang; Shuchun Liu; Aijun Zhang; Tingting Wu; Yong Zhao
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

Review 4.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 5.  Donor-specific tolerance induction in organ transplantation via mixed splenocytes chimerism.

Authors:  S Yamazaki; A Kanamoto; T Takayama
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

6.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

Authors:  Carrie L Lucas; Creg J Workman; Semir Beyaz; Samuel LoCascio; Guiling Zhao; Dario A A Vignali; Megan Sykes
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

7.  Prevention of Transplant Rejection: Can Tolerance be Achieved with Immunosuppressive Treatment?

Authors:  Conor P Delaney; Noriko Murase; Thomas E Starzl; Anthony J Demetris
Journal:  Clin Immunother       Date:  1996-08

Review 8.  Mixed hematopoietic chimerism and transplantation tolerance.

Authors:  B Nikolic; M Sykes
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 9.  Xenobiotics, chimerism and the induction of tolerance following organ transplantation.

Authors:  C P Delaney; A W Thomson; A J Demetris; T E Starzl
Journal:  Ther Immunol       Date:  1994-06

Review 10.  Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.

Authors:  Carrie Gibbons; Megan Sykes
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.